Beijing Beilu Pharmaceutical's subsidiary, Hichi Pharmaceutical, has obtained GMP certification from the Brazilian National Health Surveillance Agency (ANVISA)

Recently, the company's holding subsidiary, Hichi Pharmaceutical, passed the official on-site GMP (Good Manufacturing Practice) certification of the Brazilian National Health Surveillance Agency (Brazil ANVISA).

As an important part of the company's internationalization, Hichi Pharmaceutical continues to promote its international strategic layout. Previously, its products had obtained registration certifications from India, South Korea, Russia, Turkey, and other countries. Since 2025, its iodixanol raw materials have successively obtained market access qualifications in South Korea, India, and other countries. Brazil is the largest country in South America, and Hichi Pharmaceutical's successful ANVISA GMP certification in Brazil creates favorable conditions for the company's products to enter the Brazilian market, laying a solid foundation for further expanding the Brazilian and other international markets, and is of positive significance for the overall advancement of the Group's internationalization strategy.

The company's international development strategy has made phased progress. In the first half of 2025, the company's overseas revenue reached 74.2924 million yuan, an increase of 30.41% year-on-year. Using the EU and Brazil GMP certifications as an opportunity, the company is accelerating the registration and marketing progress of its overseas products. This not only continues to rapidly increase revenue contributions, but also secures market approvals for the company's contrast agent products and Hichi Pharmaceutical's iodinated contrast agent raw materials in multiple countries, creating conditions for further opening up international markets.